Gilead Sciences Aktie News

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2025 financial res...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC). AS...

Gilead Sciences is undervalued, with a Buy rating and a DCF-based target price of $141, implying 13.4% upside. Core HIV business remains stable, while new product launches and acquisitions, notably Livdelzi, drive incremental growth and diversification. Q3 2025 results exceeded expectations, with revenue up 4% YoY and non-GAAP EPS up 22%, highlighting strong operational efficiency and margin ex...

Gilead Sciences is downgraded from "Strong Buy" to "Buy" as technical momentum has softened despite robust fundamentals. Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion, driven by HIV franchise outperformance. GILD guides for 2025 sales of $28.4–$28.7 billion and EPS of $8.05–$8.25, with HIV revenue forecast above $20B and a strong pipeline.

Gilead has successfully launched Yeztugo, the successor to its blockbuster Biktarvy. Gilead expects Yeztugo sales to reach $100 million in Q4, even though it was only approved by the FDA on June 18 last year. Even weak sales of the oncology franchise in Q3 didn't prevent Gilead's EBIT margin from reaching a three-year high of 45.2%.

Gilead Sciences' new HIV prevention drug has been added to CVS Health's commercial insurance plans, the drugmaker's CEO Daniel O'Day said at a major industry conference that kicked off on Monday in San Francisco.

Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

If a recession were to hit, it's a foregone conclusion that people won't stop taking their prescriptions, and they won't cancel major medical treatments.